
    
      The primary objective of this study was to:

      â€¢ Compare the response of CRx-102 plus DMARD therapy to placebo plus DMARD therapy in
      lowering CRP levels in rheumatoid arthritis subjects.

      The secondary objectives of this study were to:

        -  Evaluate the changes in inflammatory cytokines in subjects treated with CRx-102 plus
           DMARD therapy to placebo plus DMARD therapy.

        -  Evaluate the efficacy of CRx-102 plus DMARD therapy to placebo plus DMARD therapy using
           ACR-20 and DAS28 indices as well as fatigue scales.
    
  